Sponsor:
Insel Gruppe AG, University Hospital Bern
Code:
NCT01257269
Conditions
Thrombotic Thrombocytopenic Purpura
Congenital Thrombotic Thrombocytopenic Purpura
Familial Thrombotic Thrombocytopenic Purpura
Thrombotic Thrombocytopenic Purpura, Congenital
Upshaw-Schulman Syndrome
Eligibility Criteria
Sex: All
Age: 0+
Healthy Volunteers: Not accepted
Interventions
Observation
Brief summary:
Conditions
Thrombotic Thrombocytopenic Purpura
Congenital Thrombotic Thrombocytopenic Purpura
Familial Thrombotic Thrombocytopenic Purpura
Thrombotic Thrombocytopenic Purpura, Congenital
Upshaw-Schulman Syndrome
Study ID
NCT01257269
Start date
Oct, 2006
Status verified date
Oct, 2023
Completion date
Oct, 2030
Anticipated
Primary completion date
Oct, 2030
Anticipated
Eligibility Criteria
Sex: All
Age: 0+
Healthy Volunteers: Not accepted
Enrollment
450 participants
Anticipated
Arms
1
2
Interventions
Observation
Primary outcome measure
Central contacts
Locations
University of Oklahoma Health Sciences Center, Department of Medicine, PO Box 26901
Recruiting
Oklahoma City, Oklahoma, United States, 73126-0901
Contacts
Principal Investigator:
James N. George, M.D.
Sponsor
Insel Gruppe AG, University Hospital Bern
Last update posted
Oct 11, 2023
Last verified
Oct, 2023
Keywords
Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Insel Gruppe AG, University Hospital Bern on 2023-10-11.